Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling

Gluckman, Éliane; Broxmeyer, Hal E.; Auerbach, Arleen D.; Friedman, Henry S.; Douglas, Gordon C. C.; Devergié, A; Esperou, Hélène; Thierry, Dominique; Socié, Gérard; Lehn, Pierre; Cooper, Scott; English, Denis; Kurtzberg, Joanne; Bard, Judith; Boyse, Edward A.

doi:10.1056/nejm198910263211707

Cited by 1,872 publications

(951 citation statements)

References 14 publications

Supporting

Mentioning

898

Contrasting

Unclassified

Order By: Relevance

“…According to Noverette and Contreras [22] approximately 10,000 patients worldwide, representing dozens of diseases including malignancies, bone marrow failure, hemoglobinopathies, inborn errors of metabolism and genetic or immune disorders have now received transplants using umbilical cord blood since Gluckman and others conducted the first cord blood transplantation for Fanconi anemia in 1988 [18]. Cord blood stem cells have shown the potential to be transformed into differentiated cell types when treated in specialized cell culture conditions and can produce organ-specific tissue.…”

Section: Cord Blood Derived Stem Cells and Regenerative Medicinementioning

confidence: 99%

“…More than 25,000 allogeneic cord blood transplantations have been performed worldwide since the first cord blood transplantation in 1988 in a patient from Paris, France with Fanconi anemia using an identical HLA matched sibling [8,18]. The results, to date, are encouraging and appear at least comparable to bone marrow or peripheral blood progenitor cells as the donor source for transplants [12,13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Umbilical cord blood banking: an update

Butler

Menitove²

2011

J Assist Reprod Genet

101

View full text Add to dashboard Cite

Background Umbilical cord blood is a potential vast source of primitive hematopoietic stem and progenitor cells available for clinical application to reconstitute the hematopoietic system and/or restore immunological function in affected individuals requiring treatment. Cord blood can be used as an alternative source for bone marrow transplantation and its use is developing into a new field of treatment for pediatric and adult patients presenting with hematological disorders, immunological defects and specific genetic diseases. Discussion More than 25,000 allogeneic cord blood transplantations have been performed worldwide since the first cord blood transplantation in 1988. There are two banking options for storing umbilical cord blood [private (family) and public]. Cord blood stored in private banks are used for either autologous or allogeneic transplants for the infant donor or related family members but private cord blood banks are not searchable or available to the public. More than 780,000 cord blood units are stored in over 130 private cord blood banks, worldwide, and over 400,000 units in more than 100 quality controlled public cord blood banks.Conclusions Researchers continue to evaluate the usefulness of cord blood cells in treating human diseases or disorders for purposes other than hematological disorders including heart disease, strokes, brain or spinal cord injuries and cancer. This review summarizes the status of umbilical cord blood banking, its history and current and potential use in the treatment of human disease.

show abstract

Section: Cord Blood Derived Stem Cells and Regenerative Medicinementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Umbilical cord blood banking: an update

Butler

Menitove²

2011

J Assist Reprod Genet

101

View full text Add to dashboard Cite

show abstract

“…Single cord blood collections are capable of reconstituting the lymphohematopoietic system of infants and children following transplantation in vivo after myeloablative therapy (42). Single cord blood samples may also be sufficient to reconstitute hematopoiesis in adult recipients (43).…”

Section: Future Strategiesmentioning

confidence: 99%

Genetic engineering: Moral aspects and control of practice

Eisenberg

Schenker

1997

J Assist Reprod Genet

View full text Add to dashboard Cite

“…They are found in the bone marrow and they can migrate to the circulating blood only with the proper stimulation (Tong et al 1994). Umbilical cord blood (UCB) is other major source of HSC, which has been successfully used for transplantation since 1989 (Gluckman et al 1989). The possibility of creating UCB banks is a reality (Bornstein et al 2005); therefore UCB is increasingly gaining attention as a reliable source of HSC for transplantation, and it is currently an accepted therapy for several diseases.…”

Section: Introductionmentioning

confidence: 99%

Expansion of human hematopoietic stem cells for transplantation: trends and perspectives

2008

View full text Add to dashboard Cite

Umbilical cord blood transplantation is clinically limited by its low progenitor cell content. Ex vivo expansion has become an alternative to increase the cell dose available for transplants. Expansion has been evaluated in several ways such as static cultures combining growth factors or mimicking the natural microenvironment using co-culture systems. However, static cultures have a small volume capacity and therefore large-scale expansion has been addressed using bioreactors. These and other biotechnological approaches for the expansion of hematopoietic progenitors and their utility to study several aspects of hematopoietic stem cell biology are discussed here.

show abstract

Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling

Cited by 1,872 publications

References 14 publications

Umbilical cord blood banking: an update

Umbilical cord blood banking: an update

Genetic engineering: Moral aspects and control of practice

Expansion of human hematopoietic stem cells for transplantation: trends and perspectives

Contact Info

Product

Resources

About